Prospect of compassionate use in China from remdesivir. / ä»ç德西é¦å±æä¸å½åæ
ç¨è¯.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
; 46(8): 909-914, 2021 Aug 28.
Article
in English, Chinese
| MEDLINE | ID: covidwho-1439638
ABSTRACT
Compassionate use may play an important role in responding to major public health emergencies. The Jinyintan Hospital in Wuhan launched the III phase of clinical trials of antiviral drug-remdesivir on February 6, 2020. As an unapproved drug, remdesivir raised great concerns about compassionate use in China. Compassionate use is therapeutic use of unauthorized drugs outside of clinical trials. It is used for critically ill patients with life-threatening diseases and no effective treatment means in China. Patients voluntarily apply to their medical institutions. The Center for Drug Evaluation, National Medical Products Administration shall conduct scientific and reasonable review, approval, and supervision on patients' application for compassionate medication. By analyzing and comparing the current situation of compassionate use at home and abroad, it is expected to provide thinking for the development of compassionate use system in China.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Compassionate Use Trials
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
/
Chinese
Journal:
Zhong Nan Da Xue Xue Bao Yi Xue Ban
Journal subject:
Medicine
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS